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WHAT THIS PAPER ADDS
 This study shows the presence of C-type natriuretic peptide (CNP) and its receptors in human carotid atherosclerotic plaques as
evidenced by immunohistochemistry and quantitative polymerase chain reaction (PCR) analysis. Although serum CNP did not vary
with plaque complexity, there was evidence that one of the CNP receptors (NPR3) was expressed at higher levels in complex and
vulnerable plaques. Thus, our results suggest CNP involvement in regulation of plaque formation in humans and may serve as
a possible target of future diagnostic and/or improved therapy for patients at risk of plaque rupture.a r t i c l e i n f o
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Objectives: C-type natriuretic peptide (CNP) has anti-inﬂammatory, anti-proliferative and anti-migratory
properties. No data exist on the presence of CNP in human atherosclerotic plaques of the carotid artery.
Therefore, this study aimed to analyse qualitatively the distribution pattern and characteristics of CNP and
its receptors in both, early and advanced human carotid plaques, as well as in stable and unstable lesions.
In addition, the aim of this study was to evaluate CNP and its receptors as possible biomarkers to predict
plaque stability in advanced lesions.
Methods: Advanced carotid artery plaques of 40 asymptomatic patients (20 histologically stable and 20
histologically unstable) and early arteriosclerotic lesions of three patients were analysed.
Results: Serum level of CNP was similar in patients with stable and unstable plaques (196  19 pg ml1 vs.
198  25 pg ml1, p ¼ 0.948). Expression level of natriuretic peptide receptor 3 (NPR3) was signiﬁcantly
higher in unstable plaques compared to stable plaques (5.6  1.8% vs. 1.7  0.5%, p ¼ 0.045). Expression
levels of CNP and NPR2 were higher in unstable plaques but the differences were not statistically signiﬁ-
cant. The distribution pattern of CNP, NPR2 and NPR3 varied qualitatively between early and advanced
carotid plaques. No relevant histological differences were observed with respect to plaque stability.
Conclusions: This study shows the presence of CNP and its receptors in atherosclerotic plaques of human
carotid artery, with increased expression of NPR3 in histologically unstable plaques. In this study, serum
CNP was not associated with histological plaque stability. In future, larger studies are required to further
evaluate whether proteins of the CNP axis would be useful as biomarkers.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Approximately 15e20% of ischaemic strokes are caused by
arterio-arterial embolisation from ipsilateral arteriosclerotic pla-
ques of the internal carotid artery (ICA).1 Standard treatment for
stroke prevention is removal of the plaque by endarterectomy.2 It isVascular and Endovascular
Universität München, Isma-
89 4140 2167; fax: þ49 89
n).
ciety for Vascular Surgery. Publisheknown from large randomised studies that the numbers needed to
treat (NNT) to prevent one stroke in 5 years is about 18 in
asymptomatic patients, but considerably higher in subgroups.3
Better selection criteria are necessary to decrease the NNT by
identifying patients at risk (with unstable plaques) whowill beneﬁt
more from surgery. By contrast, patients with stable plaque, who
would possibly never suffer from stroke, might be offered the best
medical treatment. Besides morphologic criteria or serum factors,
several biomarkers for determination of plaque stability have
already been analysed.4 Rupture of arteriosclerotic plaque is thed by Elsevier Ltd. All rights reserved.
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Group size 3 20 20 n.a.
Median age (years  sd) 75  2.9 69.3  9.3 70.4  6.3 0.680
Male sex 2 14 (70%) 15 (75%) 0.719
Degree of ica stenosis
(%NASCET, range)
n.a. 85.4 (70e95) 86.7 (70e99) 0.768
Asymptomatic stenosis 100% 100% 100% n.a.
Risk factors
Hypertension 2 17 (85%) 16 (80%) 0.385
Hypertriglyceridemia 0 5 (25%) 6 (30%) 0.960
Hypercholesterolemia 0 9 (45%) 6 (30%) 0.971
Diabetes 0 2 (10%) 6 (30%) 0.605
Hyperuricemia 0 1 (5%) 4 (20%) 0.247
Current smoker 0 8 (40%) 11 (55%) 0.099
Renal failure 0 1 (5%) 4 (20%) 0.986
Creatinine (mg/dl) 1.26  0.3 1.0  0.3 1.3  0.6 0.120
Coronary disease 1 8 (40%) 6 (30%) 0.569
Medication
Antiplatelet therapy 2 19 (95%) 17 (85%) 0.996
Beta blockers 3 11 (55%) 8 (40%) 0.612
Ace inhibitors 0 7 (35%) 7 (35%) 0.927
Statins 2 13 (65%) 12 (60%) 0.859
Nitrates 0 1 (5%) 0 (0%) 0.985
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ment of a chronic inﬂammatory milieu,4 apoptosis or necrosis of
foam cells and vascular smooth muscle cells (SMCs),5 as well as
inﬁltration and proliferation of inﬂammatory cells like monocytes
andmacrophages.6 These inﬂammatory cells are the main source of
matrix metalloproteinases that ﬁnally cause the degradation of
extracellular matrix including the ﬁbrous cap.7
Our ﬁndings demonstrated already an anti-inﬂammatory effect
of C-type natriuretic peptide (CNP) on human monocytes,8 one of
the main players during development of arteriosclerotic plaques.9
In addition, CNP has potent anti-proliferative and anti-migratory
effects on vascular SMCs.10 The natriuretic peptide system within
plaques of human coronary arteries was already investigated by
Casco and co-workers.11 This was the ﬁrst demonstration of the
existence of an autocrine/paracrine natriuretic peptide system that
may be actively modulated during the progression of atheroscle-
rotic coronary disease. The anti-inﬂammatory, anti-proliferative
and anti-migratory properties of CNP may be relevant during
development of atherosclerosis in human carotid arteries. So far,
the existence and cytological distribution of CNP and its receptors
in human carotid arteries remain undetermined.
Therefore, the aim of this study was to validate CNP and its
receptors as possible biomarkers to predict plaque stability in
advanced lesions. In addition, this study aimed to analyse qualita-
tively the distribution pattern and characteristics of CNP and its
receptors in both, early and advanced human carotid plaques as
well as in stable and unstable lesions.
Methods
Study patients
In this retrospective study, we analysed the carotid plaques (20
histologically stable and 20 histologically unstable plaques) accord-
ing to classiﬁcation of Redgrave et al.12 of 40 patients with advanced,
asymptomatic carotid stenosis (>70%NASCET) who underwent carotid
eversion-endarterectomy (EEA). Patients have been diagnosed
within the scope of a clinical work-up or by random screening. They
were assigned to the Vascular Centre of the Klinikum rechts der Isar
Munich by their general practitioner or specialist in internal medi-
cine or angiology. The patients received an intensive work-up with
magnetic resonance imaging (MRI) or computed tomography (CT),
Doppler or duplex ultrasound of the supraaortic vessels. The degree
of stenosis (%NASCET) was determined by measuring the peak systolic
velocity (PSV) by ultrasound. Furthermore, all patients were exam-
ined pre- and postoperatively by an experienced neurologist. Only
plaques from patients without neurological symptoms or silent
ischaemia were selected for this study. Tissue sections for the anal-
ysis of early lesions (Stary IIeIII) were available from samples of the
ICA of three additional independent patients. These plaques were
adjacent to a proximal stenosis of higher degree. All samples were
processed by the same protocol as advanced lesions. As shown in
Table 1, patients having advanced lesionswerematchedwith respect
to age, sex, risk factors and medical treatment. In addition, demo-
graphic characteristics were also given in Table 1. Surgical inter-
vention was performed in accordance with the clinical practice
guidance for EEA. The study was approved by the ethics committee
of the Technische Universitaet Muenchen. Informed written consent
was obtained from every patient.
Histological analyses
Following EEA, the excited carotid plaques were ﬁxed with
formalin, segmented tomultiple pieces of 3e4mmand embedded in
parafﬁn. Each segment (3e5 sections, dependent upon the size of theplaque)was cut in slices of 2e3 mm, stained byhaematoxylin/eosin or
van Gieson’s picro-fuchsin and digitalised. In addition, consecutive
segments of two to three slices of 10 mmwere cut for RNA extraction
as described further below. All plaques were classiﬁed according to
Stary’s classiﬁcation.13 This classiﬁcation describes plaque composi-
tion in eight types from moderate atherosclerotic lesions (IeIV) to
complicated (VeVII) and VIII as advanced ﬁbrous lesion. All of the
study patients displayed the type VeVII. For the determination of
plaque stability, modiﬁed American Heart Association (AHA) char-
acterization according to Virmani and Burke14 was applied. Classiﬁ-
cation criteria were adjusted to carotid artery as described by
Redgrave et al.12 where plaques with thin (<100 mm) cap ﬁbro-
atheroma over large necrotic core (characterised by a massive
aggregate of extracellular lipid, necrotic cells, thrombosis, haemor-
rhages and few collagenous ﬁbres) were classiﬁed as unstable.13,14
In addition, tissue slides were immunostained with the following
antibodies: anti-CD31 for endothelial cells (ECs) (CD31, clone JC70A,
dilution 1:40; Dako, Hamburg, Germany); anti-CD68 for macro-
phages (anti-CD68, clone KP1, dilution 1:2000; Dako, Germany) and
anti-SMA for SMCs (anti smooth muscle actin, SMA, clone HHF35,
dilution 1:200; Dako, Germany). For immunostaining of CNP, natri-
uretic peptide receptor (NPR) 2 and NPR3, the following antibodies
were used: anti-CNP (CNP staining kit, Peninsula Laboratories, dilu-
tion 1:500); anti-NPR2 (rabbit polyclonal, dilution 1:100; abcam);
and anti-NPR3 (rabbit polyclonal, dilution 1:100; abcam). The stain-
ing for CNP was performed in accordance with the manufacturer’s
protocol. NPR2 and NPR3 were treated with the ﬁrst antibody for
60min at room temperature. The sectionswerewashed inphosphate
buffered saline (PBS) and then incubated with a biotinylated
secondary antibody (goat anti-rabbit IgG, dilution 1:200, Vector
Laboratories; Burlingame, CA, USA). CNP, NPR2 and NPR3 were
visualised by the avidinebiotin enzyme complex and the chromo-
genic substrates according to the manufacturer’s instructions.
Negative control stainedwith a corresponding non-speciﬁc antibody
(Dako) was always used for determination of staining speciﬁcity.
Extraction of messenger RNA (mRNA) and expression analysis
RNA was extracted from two to three formalin-ﬁxed slices
(10 mm) using High Pure RNA Parafﬁn Kit (Roche Diagnostics,
Table 2
Distribution pattern of CNP, NPR2 and NPR3 in early (Stary IIeIII, n ¼ 3) and
advanced (Stary IVeVII, n ¼ 40) arteriosclerotic lesions. Signal strength: Ø ¼ not
detectable, þ ¼ low, þþ ¼ moderate, þþþ ¼ strong. No differences could be
detected within the group of advanced lesions with respect to plaque stability.
Anti-CNP Anti-NPR2 Anti-NPR3
Early lesions
Endothelial cells Ø Ø Ø
Smooth muscle cells Ø þþ þ
Macrophages (if present) þ þ þ
Advanced lesions
Endothelial cells þþ þ þ
Smooth muscle cells þþ þþ þþ
Macrophages þþþ þþþ þþþ
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modiﬁed for better RNA retrieval and higher yield. In brief,
following repeated deparafﬁnisationwith xylol and dehydration by
ethanol, tissue sections were dissolved appropriately and RNA was
isolated by using a silica-gel membrane column. RNA samples were
then digested by DNase to remove any contaminated DNA, puriﬁed
again on a silica-gel membrane column and further precipitated
using sodium acetate and glycogen. Next, RNA was transcribed to
complementary DNA (cDNA) using the RevertAid cDNA Synthesis
Kit (Fermentas, St. Leon-Rot, Germany). RNA extraction and poly-
merase chain reaction (PCR) reaction were validated as described
previously.15 Furthermore, RNA was obtained subsequently from
histological slides to allow comparison of the expression level of
CNP with the corresponding plaque morphology. Due to segmen-
tation of the plaque, the slides used for RNA extraction should be
representative for the whole lesion. Quantitative expression anal-
ysis was performed with the QuantiFast SYBR Green PCR Kit (Qia-
gen, Hilden, Germany) using GeneAmp 7700 thermal cycler
(Applied Biosystems, Darmstadt, Germany). The following prede-
signed primers sets (QuantiTect Primer Assays, Qiagen, Hilden,
Germany) were used: Hs_NPPC_1_SG for CNP (#QT00211946),
Hs_NPR2_1_SG for NPR2 (#QT00013727) and Hs_NPR3_1_SG for
NPR3 (#QT00047250). All values were normalised to the expres-
sion level of the house-keeping gene Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Hs_GAPDH_2_SG, #QT01192646). Quality
of the applied primers and PCR reactionwere determined bymelting
curve analysis.
Blood sample analyses
Blood samples were taken from all patients on the morning of
surgery. For serum analysis, the blood samples were centrifuged at
2000 g for 10 min at 4 C and stored at 70 C until analysis. Blood
and serum parameters such as sodium, potassium, urea nitrogen,
creatinine and other blood sample parameters were determined
from the same blood sample according to the standardised proto-
cols in the Department of Clinical Chemistry (Klinikum rechts der
Isar, Technische Universität München). The serum level of CNP was
measured using the CNP-22 EIA Kit (Phoenix Pharmaceuticals,
Karlsruhe, Germany) according to the manufacturer’s protocol.
Statistics
Logistic regression model was used to determine differences
between groups (stable vs. unstable) adjusted for sex and age. For
nominal variables, Fisher’s exact test was applied. Correlations
between continuous variables were quantiﬁed by Pearson corre-
lation coefﬁcient (r) for normal distributed samples and adjusted
for sex and age. Data are shown as proportion (in %) or as
means  standard error. Statistical signiﬁcance was assumed at p-
values <0.05. Data were analysed using MedCalc for Windows,
version 10.0.1.0 (MedCalc Software, Mariakerke, Belgium).
Results
The distribution pattern of CNP, NPR2 and NPR3 in early and
advanced lesions is summarised in Table 2 and shown in Fig. 1.
While ECs were negative for staining of CNP and its receptors in
early lesions, intense staining was observed in ECs of advanced
plaques. In early lesions, SMCs showed moderate staining only for
NPR2. SMCs of advanced lesions demonstrated moderate expres-
sion of CNP, NPR2 and NPR3. Macrophages were rarely observed in
early lesions and showed only weak staining. By contrast, a strong
staining for CNP, NPR2 and NPR3 was seen in macrophages of
advanced plaques. Comparing stable with unstable plaques, nodifferences with respect to the distribution pattern of CNP, NPR2
and NPR3 were observed.
In addition, no signiﬁcant differenceswere found between blood
level of CNP in patients with stable and unstable carotid plaques
(196  19 pg ml1 and 198  25 pg ml1, respectively, p ¼ 0.948).
The expression levels of CNP, NPR2, NPR3 as well as the blood level
of CNP were not signiﬁcantly different with respect to risk factors
(hypertension, hyperlipidaemia, diabetes, hyperuricaemia, current
smoker, renal failure and coronary heart disease) or medication
(antiplatelet therapy, beta blockers, angiotensin-converting-
enzyme (ACE) inhibitors, statins and nitrates).
The expression levels of CNP and NPR2 appeared higher in
unstable plaques compared to stable lesions (9.5% vs. 6.9% for CNP
and 5.4% vs. 5.0% for NPR2, Fig. 2), although these differences were
not statistically signiﬁcant (p ¼ 0.199 and p ¼ 0.834, respectively).
By contrast, expression levels of NPR3 were signiﬁcantly increased
in unstable plaques compared to stable plaques (5.6  1.8% vs.
1.7  0.5%, p ¼ 0.045).
Correlation analysis indicated that the expression levels of CNP
and NPR3 (r ¼ 0.486, p ¼ 0.003) were signiﬁcantly correlated
(Table 3). By contrast, expression level of CNP and NPR2 (r ¼ 0.330,
p ¼ 0.053) were not signiﬁcantly correlated. In addition, no
signiﬁcant correlation was found for serum level of CNP with
expression level of CNP, NPR2 and NPR3 (Table 3).
Discussion
CNP is highly conserved among species and represents the most
ancient member of the natriuretic peptide family.16 Since the
discovery of CNP in 1990, many physiological and pathophysio-
logical functions had been explored. CNP stimulates selectively the
human NPR2, which in turn activates the cyclic guanosine mono-
phosphate (cGMP)-dependent kinase (cGK) by elevating the
intracellular level of cGMP.17 In addition, CNP binds NPR3 that
deactivates protein kinase A by Gi-protein-dependent inhibition of
adenylcyclase.18 Besides other functions, CNP inhibits neointimal
restenosis,19 and reduces vascular constrictive remodeling20 and
cardiac ischaemia-reperfusion injury.17 It also plays a pivotal role in
a special bone growth disorder,21 is over-expressed in sepsis22 and
is involved in the function of the reproduction organs.23
Distribution pattern of CNP and its receptors
In accordance to Casco et al., who demonstrated for the ﬁrst
time the presence of a natriuretic peptide system within coronary
arteriosclerotic plaques, we show in our study that CNP and its
receptors are also strongly expressed in advanced atherosclerotic
plaques of internal carotid arteries (Fig. 1, Table 2). While CNP was
moderately expressed by ECs and SMCs in early coronary plaques,
no evidence for expression in early lesions of the ICAwas observed.
In contrast to coronary lesions, expression of NPR2 could be
Figure 1. aec: Immunostaining of CNP, NPR2 and NPR3 in early (upper part) and advanced arteriosclerotic (lower part) lesions. a ¼ endothelium, b ¼ smooth muscle cells,
c ¼ macrophages. Average intenstity of staining is indicated in the lower right corner of each image (see also Table 2).
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Figure 2. Expression levels of CNP, NPR2 and NPR3 by using quantitative PCR. Values
are given in % of the expression level of GAPDH. Expression of NPR3 is signiﬁcantly
higher in unstable plaques compared to stable plaques.
A. Kuehnl et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 649e654 653detected in SMCs of ICA plaques in early and advanced plaques.
Macrophages showed moderate expression in early plaques and
intensive expression in advanced lesions in ICA plaques. These
results support the assumption that expression of CNP in macro-
phages is modulated during the progression of atherosclerotic
plaque in both coronary and carotid arteries. Macrophages seemed
to be a major source of CNP within the plaques. As far as detectable
by immunohistochemistry, no differences were found between
stable and unstable plaque. Based on our present data, no conclu-
sions with respect to plaque vulnerability could be drawn from
immunohistochemistry. It may be possible that co-localisation of
CNP and its receptors by double- or triple staining would have
revealed further information. Nevertheless, the histological distri-
bution pattern indicates that CNP and its receptors are modulated
during the progression of plaque formation. Whether CNP plays
a causative or passive role could not be inferred from this non-
experimental study. Nevertheless it is known that overexpression
of CNP is induced by, for example, tumour necrosis factor (TNF)-a,
which is typically released from macrophages after entering sub-
endothelial space and coming into contact with oxidised low-
density lipoprotein (LDL).24 CNP was shown to inhibit
cyclooxygenase-2 (COX-2) in mouse bone-marrow macrophages25
as well as expression of inﬂammatory cytokines in peripheral
blood human monocytes.8 Thus, it might be possible that CNP is
a body’s own mechanism to limit intra-plaque inﬂammation. Both,
acquired or genetically determined limitation of CNP production or
reduced responsiveness of receptors might be one cause for indi-
vidual liability to atherosclerosis.
Serum level of CNP
The mean plasma level of CNP was 197 pg ml1 (range
30e480 pg ml1) without any signiﬁcant differences betweenTable 3
Correlation analyses between the expression levels of CNP, NPR2, NPR3 and serum
CNP. All results are adjusted for sex and age. *p ¼ 0.003.
Pearson correlation
coefﬁcient (r)
CNPmRNA NPR2mRNA NPR3mRNA CNPserum
CNPmRNA n.a. 0.330 0.486* 0.125
NPR2mRNA 0.330 n.a. 0.187 0.057
NPR3mRNA 0.486* 0.187 n.a. 0.232
CNPserum 0.125 0.057 0.232 n.a.patients with stable or unstable plaques (p ¼ 0.839). However, it
must be mentioned that potential existing difference might not be
detected due to the small sample size. The concentration of CNP in
blood was within the range reported in the literature for healthy
controls (0.680.37pgml1,272.70.2 pgml,28 4.20.4 pgml1,29
3114 pgml1,30 and 800 270 pgml1,31). With respect to serum
levels, it must be mentioned that the reported values were
measured with different methods in healthy subjects (control
groups), who were predominantly younger and had no reported
evidence for inﬂammation or arteriosclerosis. So far, no data exist
concerning the half-life of CNP or impact of medication on CNP
blood level.When envisioning half-life of A-type natriuretic peptide
(ANP) (2 min32) or B-type natriuretic peptide (BNP) (20 min33),
speciﬁcs of blood sample collection like time of day or temperature
of storage until analysis may have relevant inﬂuence on CNP serum
level. These issuesmayexplain thewide range of CNP blood levels in
the previous studies. In the future, speciﬁcs of collection and pro-
cessing of the blood samples have to be analysed and optimised. In
addition, newer methods like measurement of NT-proCNP27,32,33
may further improve accuracy.
Expression and correlation analyses
Our current data adduce no evidence that expression levels of
CNP and its receptors are correlated with the presence of risk
factors or application of medication for vulnerable carotid plaques.
This might be due to the relatively small group size, which is not
able to read-out the weak effects of risk factors and medication on
expression levels of CNP and its receptors. So far, there are no
relevant studies investigating the effect of risk factors or medica-
tion on the expression level of CNP and its receptors. Thus, no
further conclusions can be drawn from our results.
Expression of CNPwithin the plaquewas signiﬁcantly correlated
with the expression levels of NPR3. This can be explained by
general activation of the CNP system during progression of arte-
riosclerotic lesions. Overexpression of CNP during plaque progres-
sionwas also found in other studies,11 but expression levels of NPR2
and NPR3were not different between early and advanced lesions of
coronary arteries. No published data concerning correlation anal-
yses of expression levels of CNP and its receptors were found.
Within advanced atherosclerotic plaques (Fig. 2), expression levels
of CNP and NPR2 were increased in unstable plaques, but not
signiﬁcantly different between the study groups. Thus, these factors
are so far not applicable to distinguish between patients with stable
plaques and unstable carotid plaques. By contrast, expression of
NPR3 was signiﬁcantly higher in patients with unstable lesions. In
addition, the prediction of plaque vulnerability, as determined by
expression of NPR3 has to be measured preoperatively to conclude
therapeutic options. In the future, measurement of NPR3 expres-
sion might be possible using positron emission tomography or
scintigraphy with tracers targeting NPR3.
Limitation of the study
We acknowledge that no quantiﬁcation of lesion stability, for
example, by inﬂammatory cell count or matrix metalloproteinase
(MMP) expression has been included. However, it is tomention that
such biomarkers do not distinguish between stable and unstable
plaques, merely the plaque progression. Therefore, lesion stability
was determined by means of histology as described by Redgrave
et al.,12 who have analysed over 500 carotid plaques to assess the
minimal cap thickness that highly corresponds with the clinical
event. Furthermore, comparison of early and advanced plaques was
only possible in a qualitative way, due to very small number of
specimens of early lesions. For quantitative analysis, it would have
A. Kuehnl et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 649e654654been necessary to have a well-sized group containing exclusively
specimens of early plaques.
However, in summary, this study shows the presence of CNP and
its receptors in human carotid atherosclerotic plaques as evidenced
by immunohistochemistry and quantitative PCR analysis. Further-
more, possible evidence was found indicating the modulation of
CNP and its receptors in the vascular wall during plaque formation.
In addition, this study shows that expression of CNP receptors is
clearly different in histologically stable and histologically unstable
plaques. Thus, our results suggest an involvement of CNP and its
receptors (either passive or active) in regulation of plaque forma-
tion in humans and may serve as a possible target of future diag-
nostic and/or improved therapy for patients at risk of plaque
rupture. Further prospective studies are necessary to evaluate the
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